Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033934 | 0.79 | P2RX7 (0.57) | P2RX7MKNK1MAPTPARP1TNKS2 | |
| SCHEMBL16033973 | 0.79 | P2RX7 (0.55) | P2RX7MKNK1MAPTADORA1PARP1 | |
| SCHEMBL31518819 | 0.78 | ADORA1 (0.46) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL9951760 | 0.78 | ESR2 (0.48) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL29899522 | 0.77 | MTOR (0.39) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL19959250 | 0.77 | ADORA1 (0.49) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL29899537 | 0.77 | MKNK1 (0.46) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL1497077 | 0.77 | MKNK1 (0.48) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL30603343 | 0.77 | ESR2 (0.47) | MKNK1MAPTADORA1PARP1TNKS2 | |
| SCHEMBL16034797 | 0.77 | P2RX7 (0.59) | P2RX7GPR119MKNK1MAPTADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| EP-3112366-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3112366-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| EP-2970271-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-08 | — | — | EP | disclosed |
| US-20160024082-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024082-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024082-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | disclosed |
| US-9096596-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-04 | — | — | US | disclosed |
| US-9096596-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-04 | — | — | US | disclosed |
| US-9096596-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-04 | — | — | US | disclosed |
| WO-2014152589-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275120-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275120-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275120-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323032-B2 | P2X7 Modulators | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885GPR119 82/4885MKNK1 2673/4885 |
| US-20140275120-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885GPR119 96/4885MKNK1 2704/4885 |
| US-20160024082-A1 | P2X7 MODULATORS | P2RX1, P2RX5, P2RX3 | P2RX7 4/4885GPR119 35/4885MKNK1 1967/4885 |
| US-20180072724-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885GPR119 82/4885MKNK1 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.